ISLAND PHARMACEUTICALS LIMITED (ILA)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ILA

ILA - ISLAND PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index:

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.37

12 Oct
2026

0.005

OPEN

$0.37

1.37%

HIGH

$0.37

15,958

LOW

$0.37

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 20222023202420252026
EPS Basic xxxxxxxxxxxx-3.6
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxx4.5
Net Operating Cash Flow xxxxxxxxxxxx-4.8 M
Net Profit Margin xxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20222023202420252026
Return on Capital Employed xxxxxxxxxxxx-95.50 %
Return on Invested Capital xxxxxxxxxxxx-95.50 %
Return on Assets xxxxxxxxxxxx-91.62 %
Return on Equity xxxxxxxxxxxx-95.50 %
Return on Total Capital xxxxxxxxxxxx-103.01 %
Free Cash Flow ex dividends xxxxxxxxxxxx-4.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20222023202420252026
Short-Term Debt xxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxx13 M
Price To Book Value xxxxxxxxxxxx8.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20222023202420252026
Capex xxxxxxxxxxxx0.8 M
Capex % of Sales xxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx11 M
Research & Development xxxxxxxxxxxx3 M
Investments - Total xxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Research as a Service (RaaS)

07/10/2026

-1

No Rating

1.37%

Island Pharmaceuticals has commenced manufacturing of the active ingredient in GMP-grade Galidesivir and the first 5kg batch should be available by the end of October, to be used in Uganda for the current Bundibugyo Ebola outbreak.

A second batch is planned by the end of November.

Research as a Service (RaaS) notes the disease continues to spread, with confirmed cases increasing by 56% since August to 8,127, and 3,926 deaths as of September 27.

The commencement of manufacturing is seen as an important milestone, bringing the company closer to generating human Ebola data.

Valuation of $1.60 is unchanged.

Research as a Service research does not carry any targets, ratings or recommendations. Investors can draw conclusions from valuations and commentary.

FORECAST
Research as a Service (RaaS) forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -4.70 cents.
Access Extra Coverage Research History >

ILA STOCK CHART

FNArena News on ILA

1
Australian Broker Call *Extra* Edition – Oct 07, 2026

Oct 07 2026 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Sep 01, 2026

Sep 01 2026 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Aug 04, 2026

Aug 04 2026 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Jul 09, 2026

Jul 09 2026 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Jun 18, 2026

Jun 18 2026 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Telix Aims For A Strategic Isotope Supply Chain

Sep 24 2026 - Australia
2
CSL’s FY26 Suggests The Downtrend Is Done

Aug 19 2026 - Australia
3
Strong Result, Can Telix Continue To Deliver?

Jul 22 2026 - Australia
4
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
5
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
6
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
7
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
8
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
9
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
10
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals